← Back to all trials
Active Not Recruiting
NCT04556773
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 138
Sponsor: AstraZeneca
Location: Research Site Commack New York
Summary
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
Eligibility Criteria
Key Inclusion Criteria:
* Patients must be at least 18 years of age
* Male or female patients who have pathologically documented breast cancer that:
1. Has a history of HER2-low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) with a validated assay
2. Is documented as HR+ (either ER and/or PgR positive \[ER or PgR ≥1%\]) or ER and PgR negative (ER and PgR \
Source: ClinicalTrials.gov (NCT04556773). StuddyBuddy aggregates publicly available trial information.
